Rydzewski NR, et al. - Using the National Cancer Database, researchers examined practice patterns of stereotactic radiosurgery (SRS) use for brain metastases, concentrating on short-term mortality. Analysis of short-term mortality following treatment for brain metastases allows insight into national treatment patterns and related outcomes. Findings suggested that approximately 1 in 5 patients who receive SRS and approximately 1 in 3 patients 70 and older who receive SRS die within 90 days of treatment. Most notably in patients over the age of 70, some degree of SRS overutilization of SRS was suggested, but other patient populations as well. Mortality was 30.2% at 90 days for patients 70 and older who received SRS.